Injection of insanity

29 August 2016 By Richard Beales

The $23 bln pharma group, under fire for raising prices, is launching generics identical to its branded anti-allergy injectors at half the price. The unusual move raises questions about Mylan’s motives. Even if they’re genuine, it’s an indictment of a byzantine market structure.

This content is for Subscribers only

To access full content you must be a subscriber. Please use the following link to request a trial.


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)